New HTA budget impact guidelines must not dissuade industry from investing in Ireland, says IPHA
This article was originally published in Scrip
As the Irish government steels itself to request the European Union and the International Monetary Fund for a bailout of up to €90 billion to prop up its debt ridden banks, the Irish pharmaceutical industry association (IPHA) has cautioned against measures that might threaten international pharma investors. In particular, IPHA warns that new health technology appraisal guidelines published today on budget impact analysis (BIA) must not "result in any inadvertent delay in patient access to new health technologies" or dissuade companies from launching in Ireland.
You may also be interested in...
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.